INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

BP=blood pressure; CV=cardiovascular; CVD=cardiovascular disease; T2D=type 2 diabetes.

*Results were seen as early as 12 weeks.

Prespecified secondary endpoint.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. 3. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. 4. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.